Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?

Cancer treatment reviews - 1 Jul 2016

Gargiulo Piera, Della Pepa Chiara, Berardi Simona, Califano Daniela, Scala Stefania, Buonaguro Luigi, Ciliberto Gennaro, Brauchli Peter, Pignata Sandro

Abstract excerpt

Endometrial Cancer (EC) is still a challenge for gynecological oncologists because the treatment of the advanced disease remains an unmet need for patients. The Cancer Genome Atlas Research Network (TCGA) recently provided a comprehensive genomic and transcriptomic analysis of EC, offering a new classification of the disease, based on genetic features, which defines four subgroups of cancer rather than the two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Immunotherapy

Share to Microsatellite Instability

Share to Poly-ADP-Ribose Binding Proteins

Share to Programmed Cell Death 1 Receptor

Share to Tumor Microenvironment

Source

Identifiers

PMID: 27362548
DOI: 10.1016/j.ctrv.2016.06.008

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?PMID 27362548Read ↗

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activitySemantic proximity Read ↗

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitionSemantic proximity Read ↗

The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive ReviewSemantic proximity Read ↗

New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.Semantic proximity Read ↗

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.Semantic proximity Read ↗

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.Semantic proximity Read ↗

Molecular classification of endometrial carcinoma, is it the new era of precision medicine?Semantic proximity Read ↗

Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.Semantic proximity Read ↗

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.Semantic proximity Read ↗

The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.Semantic proximity Read ↗

Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapySemantic proximity Read ↗

Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.